Tissue Factor Coagulation Pathway: A New Therapeutic Target in Atherothrombosis

Journal of Cardiovascular Pharmacology

Volumn 43, Issue 5, 2004, Pages 669-676

  Viles Gonzalez, Juan F ^a   Anand, Sunil X ^a   Zafar, M Urooj ^a   Fuster, Valentin ^a   Badimon, Juan J ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Antithrombotics; Atherothrombosis; Factor x inhibitors; Thrombin inhibitors; Tissue factor

Indexed keywords

2 [4 [(1 ACETIMIDOYL 3 PYRROLIDINYL)OXY]PHENYL] 3 (7 AMIDINO 2 NAPHTHYL)PROPIONIC ACID; 3 [3 (AMINOIMINOMETHYL)PHENYL] N (2' AMINOSULFONYL 1,1' BIPHENYL 4 YL) 4,5 DIHYDRO 5 (1H TETRAZOL 1 YLMETHYL) 5 ISOXAZOLECARBOXAMIDE; ACETYLSALICYLIC ACID; ANTISTATIN; ARGATROBAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; BLOOD CLOTTING FACTOR 7A INHIBITOR; CLOPIDOGREL; DALTEPARIN; DESULFATOHIRUDIN; DITHIOCARBAMIC ACID; DX 9056; EFEGATRAN; ENOXAPARIN; FONDAPARINUX; HEPARIN; HIRUDIN; HIRULOG; INOGATRAN; MELAGATRAN; NAPSAGATRAN; NEMATODE ANTICOAGULANT PROTEIN C2; RAZAXABAN; THROMBIN INHIBITOR; THROMBOPLASTIN; TICK ANTICOAGULANT PEPTIDE; TISSUE FACTOR MONOCLONAL ANTIBODY; TISSUE FACTOR PATHWAY INHIBITOR; UNCLASSIFIED DRUG; XIMELAGATRAN; YM 416;

ATHEROMA; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; ATHEROTHROMBOSIS; BLEEDING; BLOOD CLOTTING; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; HEART MUSCLE ISCHEMIA; HUMAN; MORBIDITY; MORTALITY; PRIORITY JOURNAL; REVIEW; THROMBOGENESIS; THROMBOSIS;

ARTERIOSCLEROSIS; FACTOR VII; FACTOR X; HUMANS; THROMBIN; THROMBOPLASTIN;

EID: 2042449992     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-200405000-00009     Document Type: Review

References (59)

1. Tremoli E, Camera M, Toschi V, et al. Tissue factor in atherosclerosis. Atherosclerosis. 1999;144:273-283.
2. Wilcox JN, Smith KM, Schwartz SM, et al. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci U S A. 1989;86:2839-2843.
3. Virmani R, Kolodgie FD, Burke AP, et al. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 2000;20:1262-1275.
4. Zaman AG, Helfi G, Worthley SG, et al. The role of plaque rupture and thrombosis in coronary artery disease. Atherosclerosis. 2000:149:251-266.
5. Viles-Gonzalez JF, Badimon JJ. Atherothrombosis: the role of tissue factor. Int J Biochem Cell Biol. 2004;36:25-30.
6. Giesen PL, Fyfe BS, Fallon JT, et al. Intimal tissue factor activity is released from the arterial wall after injury. Thromb Haemost. 2000;83:622-628.
7. Giesen PL, Rauch U, Bohrmann B, et al. Blood-borne tissue factor: another view of thrombosis. Proc Natl Acad Sci U S A. 1999;96:2311-2315.
8. Sambola A, Osende J, Hathcock J, et al. Role of risk factors in the modulation of tissue factor activity and blood thrombogenicity. Circulation. 2003;107:973-977.
9. Osende JI, Badimon JJ, Fuster V, et al. Blood thrombogenicity in type 2 diabetes mellitus patients is associated with glycemic control. J Am Coll Cardiol. 2001;38:1307-1312.
10. Toschi V, Gallo R, Lettino M, et al. Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. Circulation. 1997;95:594-599.
11. Moons AH, Levi M, Peters RJ. Tissue factor and coronary artery disease. Cardiovasc Res. 2002;53:313-325.
12. Fernandez-Ortiz A, Badimon JJ, Falk E, et al. Characterization of the relative thrombogenicity of atherosclerotic plaque components: implications for consequences of plaque rupture. J Am Coll Cardiol. 1994;23:1562-1569.
13. Mallat Z, Tedgui A. Current perspective on the role of apoptosis in atherothrombotic disease. Circ Res. 2001;88:998-1003.
14. Lewis JC, Bennett-Cain AL, DeMars CS, et al. Procoagulant activity after exposure of monocyte-derived macrophages to minimally oxidized low density lipoprotein. Co-localization of tissue factor antigen and nascent fibrin fibers at the cell surface. Am J Pathol. 1995;147:1029-1040.
15. Colli S, Lalli M, Rise P, et al. Increased thrombogenic potential of human monocyte-derived macrophages spontaneously transformed into foam cells. Thromb Haemost. 1999;81:576-581.
16. Mach F, Schonbeck U, Bonnefoy JY, et al. Activation of monocyte/macrophage functions related to acute atheroma complication by ligation of CD40: induction of collagenase, stromelysin, and tissue factor. Circulation. 1997;96:396-399.
17. Bavendiek U, Libby P, Kilbride M, et al. Induction of tissue factor expression in human endothelial cells by CD40 ligand is mediated via activator protein 1, nuclear factor kappa B, and Egr-1. J Biol Chem. 2002;277:25032-25039.
18. Anand SX, Viles-Gonzalez JF, Badimon JJ, et al. Membrane-associated CD40L and sCD40L in atherothrombotic disease. Thromb Haemost. 2003;90:377-384.
19. Mazzolai L, Silacci P, Bouzourene K, et al. Tissue factor activity is upregulated in human endothelial cells exposed to oscillatory shear stress. Thromb Haemost. 2002;87:1062-1068.
20. Golino P, Ragni M, Cirillo P, et al. Effects of tissue factor induced by oxygen free radicals on coronary flow during reperfusion. Nat Med. 1996:2:35-40.
21. Hjortoe GM, Petersen LC, Albrektsen T, et al. Tissue factor-factor VIIa specific up-regulation of IL-8 expression in MDA-MB-231 cells is mediated via PAR-2 and results in increased cell migration. Blood 2004.
22. Rauch U, Bonderman D, Bohrmann B, et al. Transfer of tissue factor from leukocytes to platelets is mediated by CD15 and tissue factor. Blood. 2000;96:170-175.
23. Rauch U, Crandall J, Osende JI, et al. Increased thrombus formation relates to ambient blood glucose and leukocyte count in diabetes mellitus type 2. Am J Cardiol. 2000;86:246-249.
24. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71-86.
25. Hirsh J. Oral anticoagulant drugs. N Engl J Med. 1991;324:1865-1875.
26. Hirsh J. Heparin. N Engl J Med. 1991;324:1565-1574.
27. Pawashe AB, Golino P, Ambrosio G, et al. A monoclonal antibody against rabbit tissue factor inhibits thrombus formation in stenotic injured rabbit carotid arteries. Circ Res. 1994;74:56-63.
28. Harker LA, Hanson SR, Wilcox JN, et al. Antithrombotic and antilesion benefits without hemorrhagic risks by inhibiting tissue factor pathway. Haemostasis. 1996;26(Suppl 1):76-82.
29. Cirillo P, Golino P, Ragni M, et al. Long-lasting antithrombotic effects of a single dose of human recombinant, active site-blocked factor VII: insights into possible mechanism(s) of action. J Thromb Haemost. 2003;1:992-998.
30. Lev EI, Marmur JD, Zdravkovic M, et al. Antithrombotic effect of tissue factor inhibition by inactivated factor VIIa: an ex vivo human study. Arterioscler Thromb Vasc Biol. 2002;22:1036-1041.
31. Lee AY, Vlasuk GP. Recombinant nematode anticoagulant protein c2 and other inhibitors targeting blood coagulation factor VIIa/tissue factor. J Intern Med. 2003;254:313-321.
32. Lee A, Agnelli G, Buller H, et al. Dose-response study of recombinant factor VIIa/tissue factor inhibitor recombinant nematode anticoagulant protein c2 in prevention of postoperative venous thromboembolism in patients undergoing total knee replacement. Circulation. 2001;104:74-78.
33. Moons AH, Peters RJ, Bijsterveld NR, et al. Recombinant nematode anticoagulant protein c2, an inhibitor of the tissue factor/factor VIIa complex, in patients undergoing elective coronary angioplasty. J Am Coll Cardiol. 2003;41:2147-2153.
34. Roque M, Reis ED, Fuster V, et al. Inhibition of tissue factor reduces thrombus formation and intimal hyperplasia after porcine coronary angioplasty. J Am Coll Cardiol. 2000;36:2303-2310.
35. Kopp CW, Hoelzenbein T, Steiner S, et al. Inhibition of restenosis by tissue factor pathway inhibitor: in vivo and in vitro evidence for suppressed monocyte chemoattraction and reduced gelatinolytic activity. Blood. 2003.
36. Abraham E, Reinhart K, Svoboda P, et al. Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study. Crit Care Med. 2001;29:2081-2089.
37. de Jonge E, Dekkers PE, Creasey AA, et al. Tissue factor pathway inhibitor dose-dependently inhibits coagulation activation without influencing the fibrinolytic and cytokine response during human endotoxemia. Blood. 2000;95:1124-1129.
38. Abraham E, Reinhart K, Opal S, et al. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA. 2003;290:238-247.
39. Atsuchi N, Nishida T, Marutsuka K, et al. Combination of a brief irrigation with tissue factor pathway inhibitor (TFPI) and adenovirus-mediated local TFPI gene transfer additively reduces neointima formation in balloon-injured rabbit carotid arteries. Circulation. 2001;103:570-575.
40. Cavusoglu E, Chen I, Rappaport J, et al. Inhibition of tissue factor gene induction and activity using a hairpin ribozyme. Circulation. 2002;105:2282-2287.
41. Drollinger AG, Netser JC, Rodgers GM. Dithiocarbamates ameliorate the effects of endotoxin in a rabbit model of disseminated intravascular coagulation. Semin Thromb Hemost. 1999;25:429-433.
42. Turpie AG, Bauer KA, Eriksson BI, et al. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med. 2002;162:1833-1840.
43. Turpie AG, Bauer KA, Eriksson BI, et al. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial. Lancet. 2002;359:1721-1726.
44. Bauer KA, Eriksson BI, Lassen MR, et al. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med. 2001;345:1305-1310.
45. Lassen MR, Bauer KA, Eriksson BI, et al. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison. Lancet. 2002;359:1715-1720.
46. Eriksson BI, Bauer KA, Lassen MR, et al. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med. 2001;345:1298-1304.
47. Gresele P, Agnelli G. Novel approaches to the treatment of thrombosis. Trends Pharmacol Sci. 2002;23:25-32.
48. Shimbo D, Osende J, Chen J, et al. Antithrombotic effects of DX-9065a, a direct factor Xa inhibitor: a comparative study in humans versus low molecular weight heparin. Thromb Haemost. 2002;88:733-738.
49. Weitz JI, Crowther M. Direct thrombin inhibitors. Thromb Res. 2002;106:V275-V284.
50. Vermeer F, Vahanian A, Fels PW, et al. Argatroban and alteplase in patients with acute myocardial infarction: the ARGAMI Study. J Thromb Thrombolysis. 2000;10:233-240.
51. Lewis BE, Wallis DE, Leya F, et al. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch Intern Med. 2003;163:1849-1856.
52. McKeage K, Plosker GL. Argatroban. Drugs. 2001;61:515-22; discussion 523-524.
53. Francis CW, Berkowitz SD, Comp PC, et al. Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement. N Engl J Med. 2003;349:1703-1712.
54. Colwell CW, Berkowitz SD, Davidson BL, et al. Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement. A randomized, double-blind study. J Thromb Haemost. 2003;1:2119-2130.
55. Eriksson BI, Bergqvist D, Kalebo P, et al. Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO 11 randomised trial. Lancet. 2002;360:1441-1447.
56. Petersen P, Grind M, Adler J. Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. SPORTIF II: a dose-guiding, tolerability, and safety study. J Am Coll Cardiol. 2003;41:1445-1451.
57. Halperin JL. Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: Rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V). Am Heart J. 2003;146:431-438.
58. Wallentin L, Wilcox RG, Weaver WD, et al. Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial. Lancet. 2003;362:789-797.
59. Sarich TC, Osende JI, Eriksson UG, et al. Acute antithrombotic effects of ximelagatran, an oral direct thrombin inhibitor, and r-hirudin in a human ex vivo model of arterial thrombosis. J Thromb Haemost. 2003;1:999-1004.